Is DiaMedica Therapeutics Stock a Good Investment?
DiaMedica Therapeutics Investment Advice | DMAC |
- Examine DiaMedica Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research DiaMedica Therapeutics' leadership team and their track record. Good management can help DiaMedica Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact DiaMedica Therapeutics' business and its evolving consumer preferences.
- Compare DiaMedica Therapeutics' performance and market position to its competitors. Analyze how DiaMedica Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if DiaMedica Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about DiaMedica Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in DiaMedica Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if DiaMedica Therapeutics is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Good | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine DiaMedica Therapeutics Stock
Researching DiaMedica Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 26.0% of the company shares are held by company insiders. The book value of DiaMedica Therapeutics was currently reported as 1.35. The company recorded a loss per share of 0.56. DiaMedica Therapeutics last dividend was issued on the 15th of November 2018. The entity had 1:20 split on the 15th of November 2018.
To determine if DiaMedica Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding DiaMedica Therapeutics' research are outlined below:
| DiaMedica Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (19.38 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (18.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: DiaMedica Therapeutics Reports Q3 2024 Financial Results - TipRanks |
DiaMedica Therapeutics Quarterly Liabilities And Stockholders Equity |
|
DiaMedica Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in DiaMedica Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to DiaMedica Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact DiaMedica Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises DiaMedica Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-08 | 2024-03-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2023-08-14 | 2023-06-30 | -0.18 | -0.16 | 0.02 | 11 | ||
2020-08-11 | 2020-06-30 | -0.15 | -0.17 | -0.02 | 13 | ||
2024-08-07 | 2024-06-30 | -0.16 | -0.13 | 0.03 | 18 | ||
2022-11-09 | 2022-09-30 | -0.15 | -0.12 | 0.03 | 20 | ||
2019-03-19 | 2018-12-31 | -0.2 | -0.23 | -0.03 | 15 | ||
2023-05-15 | 2023-03-31 | -0.16 | -0.2 | -0.04 | 25 | ||
2021-08-11 | 2021-06-30 | -0.21 | -0.17 | 0.04 | 19 |
Know DiaMedica Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as DiaMedica Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading DiaMedica Therapeutics backward and forwards among themselves. DiaMedica Therapeutics' institutional investor refers to the entity that pools money to purchase DiaMedica Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ronald Blue Trust, Inc. | 2024-09-30 | 44.2 K | Susquehanna International Group, Llp | 2024-06-30 | 43.4 K | Catalyst Financial Partners Llc | 2024-09-30 | 38.5 K | Jefferies Financial Group Inc | 2024-09-30 | 26 K | Citigroup Inc | 2024-09-30 | 22.1 K | Stonebridge Capital Advisors Llc | 2024-09-30 | 17.5 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 17 K | Bnp Paribas Arbitrage, Sa | 2024-06-30 | 15.2 K | Jane Street Group Llc | 2024-06-30 | 15.1 K | Cooperman Leon G | 2024-09-30 | 1.5 M | Vanguard Group Inc | 2024-09-30 | 1 M |
DiaMedica Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 222.78 M.Market Cap |
|
DiaMedica Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.36) | (0.38) | |
| Return On Capital Employed | (0.41) | (0.43) | |
| Return On Assets | (0.36) | (0.38) | |
| Return On Equity | (0.38) | (0.40) |
Determining DiaMedica Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if DiaMedica Therapeutics is a good buy. For example, gross profit margin measures DiaMedica Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of DiaMedica Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of DiaMedica Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, DiaMedica Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of DiaMedica Therapeutics' management manipulating its earnings.
Evaluate DiaMedica Therapeutics' management efficiency
DiaMedica Therapeutics has return on total asset (ROA) of (0.2354) % which means that it has lost $0.2354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3518) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 28, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 56.4 M, whereas Non Currrent Assets Other are forecasted to decline to (0.94).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.57 | 1.05 | |
| Tangible Book Value Per Share | 1.57 | 1.65 | |
| Enterprise Value Over EBITDA | (4.58) | (4.80) | |
| Price Book Value Ratio | 1.81 | 1.72 | |
| Enterprise Value Multiple | (4.58) | (4.80) | |
| Price Fair Value | 1.81 | 1.72 | |
| Enterprise Value | 33.8 M | 29.7 M |
Evaluating the management effectiveness of DiaMedica Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The DiaMedica Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.456 |
Basic technical analysis of DiaMedica Stock
As of the 28th of November, DiaMedica Therapeutics shows the Semi Deviation of 2.0, mean deviation of 2.47, and Downside Deviation of 2.3. DiaMedica Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.DiaMedica Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific DiaMedica Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on DiaMedica Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases DiaMedica Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
DiaMedica Therapeutics' Outstanding Corporate Bonds
DiaMedica Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. DiaMedica Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most DiaMedica bonds can be classified according to their maturity, which is the date when DiaMedica Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand DiaMedica Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing DiaMedica Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.119 | |||
| Market Risk Adjusted Performance | 33.38 | |||
| Mean Deviation | 2.47 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 2.3 | |||
| Coefficient Of Variation | 688.09 | |||
| Standard Deviation | 3.24 | |||
| Variance | 10.48 | |||
| Information Ratio | 0.1066 | |||
| Jensen Alpha | 0.459 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.1498 | |||
| Treynor Ratio | 33.37 | |||
| Maximum Drawdown | 14.14 | |||
| Value At Risk | (3.29) | |||
| Potential Upside | 5.2 | |||
| Downside Variance | 5.31 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (2.99) | |||
| Skewness | 1.22 | |||
| Kurtosis | 2.31 |
| Risk Adjusted Performance | 0.119 | |||
| Market Risk Adjusted Performance | 33.38 | |||
| Mean Deviation | 2.47 | |||
| Semi Deviation | 2.0 | |||
| Downside Deviation | 2.3 | |||
| Coefficient Of Variation | 688.09 | |||
| Standard Deviation | 3.24 | |||
| Variance | 10.48 | |||
| Information Ratio | 0.1066 | |||
| Jensen Alpha | 0.459 | |||
| Total Risk Alpha | (0.03) | |||
| Sortino Ratio | 0.1498 | |||
| Treynor Ratio | 33.37 | |||
| Maximum Drawdown | 14.14 | |||
| Value At Risk | (3.29) | |||
| Potential Upside | 5.2 | |||
| Downside Variance | 5.31 | |||
| Semi Variance | 4.0 | |||
| Expected Short fall | (2.99) | |||
| Skewness | 1.22 | |||
| Kurtosis | 2.31 |
Consider DiaMedica Therapeutics' intraday indicators
DiaMedica Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of DiaMedica Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
DiaMedica Therapeutics Corporate Filings
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
| 18th of July 2024 Other Reports | ViewVerify | |
| 10th of July 2024 Other Reports | ViewVerify |
DiaMedica Stock media impact
Far too much social signal, news, headlines, and media speculation about DiaMedica Therapeutics that are available to investors today. That information is available publicly through DiaMedica media outlets and privately through word of mouth or via DiaMedica internal channels. However, regardless of the origin, that massive amount of DiaMedica data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of DiaMedica Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of DiaMedica Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to DiaMedica Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive DiaMedica Therapeutics alpha.
DiaMedica Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards DiaMedica Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
DiaMedica Therapeutics Corporate Management
| MS MD | Independent Consultant | Profile | |
| Scott CA | CFO Sec | Profile | |
| Edward Calamai | Consulting Manufacturing | Profile | |
| Ambarish Shah | Chief Officer | Profile | |
| Lorianne MD | Chief Officer | Profile | |
| Julie CCRP | Senior Operations | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between DiaMedica Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.